IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transform how we understand, diagnose and treat disease

Contributed by: Business Wire

Logo

Business Wire logo

Tags

Technology
Biotechnology
Health
Finance
Professional Services
Artificial Intelligence
Other Science
Research
Infectious Diseases
General Health
Health Technology
Science
Data Management
Clinical Trials
biotechnology